## Mario Enrico Canonico

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1654356/publications.pdf

Version: 2024-02-01

50 papers

2,081 citations

18 h-index

430874

243625 44 g-index

51 all docs

51 docs citations

51 times ranked

2408 citing authors

#	Article	IF	CITATIONS
1	Comparison of Prasugrel and Ticagrelor Loading Doses in ST-Segment Elevation Myocardial Infarction Patients. Journal of the American College of Cardiology, 2013, 61, 1601-1606.	2.8	403
2	High Residual Platelet Reactivity After Clopidogrel Loading and Long-term Cardiovascular Events Among Patients With Acute Coronary Syndromes Undergoing PCI. JAMA - Journal of the American Medical Association, 2011, 306, 1215.	7.4	361
3	Ticagrelor Crushed Tablets Administration in STEMI Patients. Journal of the American College of Cardiology, 2015, 65, 511-512.	2.8	167
4	Morphine Is Associated With a Delayed Activity of Oral Antiplatelet Agents in Patients With ST-Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2015, 8, .	3.9	164
5	Incidence, Clinical Findings, and Outcome of Women With Left Ventricular Apical Ballooning Syndrome. American Journal of Cardiology, 2007, 99, 182-185.	1.6	156
6	Natural History of Tako-Tsubo Cardiomyopathy. Chest, 2011, 139, 887-892.	0.8	133
7	Pulmonary embolism in COVID-19 patients: prevalence, predictors and clinical outcome. Thrombosis Research, 2021, 198, 34-39.	1.7	<b>7</b> 9
8	Prevalence, Predictors, Time Course, and Long-Term Clinical Implications of Left Ventricular Functional Recovery After Mechanical Reperfusion for Acute Myocardial Infarction. American Journal of Cardiology, 2007, 100, 1718-1722.	1.6	65
9	Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: The Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study. American Heart Journal, 2014, 167, 909-914.	2.7	48
10	Dyspnoea management in acute coronary syndrome patients treated with ticagrelor. European Heart Journal: Acute Cardiovascular Care, 2015, 4, 555-560.	1.0	45
11	Morphine use and myocardial reperfusion in patients with acute myocardial infarction treated with primary PCI. International Journal of Cardiology, 2016, 221, 567-571.	1.7	41
12	Clinical conditions and echocardiographic parameters associated with mortality in COVIDâ€19. European Journal of Clinical Investigation, 2021, 51, e13638.	3.4	26
13	Beneficial Effects of Listening to Classical Music in Patients With Heart Failure: A Randomized Controlled Trial. Journal of Cardiac Failure, 2020, 26, 541-549.	1.7	24
14	Editor's Choice-Chest pain relief in patients with acute myocardial infarction. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 277-281.	1.0	23
15	From Femoral to Radial Approach in Coronary Intervention. Angiology, 2017, 68, 281-287.	1.8	21
16	Venous Thromboembolism and Cancer: A Comprehensive Review from Pathophysiology to Novel Treatment. Biomolecules, 2022, 12, 259.	4.0	21
17	The DESolve novolimus bioresorbable Scaffold: from bench to bedside. Journal of Thoracic Disease, 2017, 9, S950-S958.	1.4	20
18	The tug-of-war between coagulopathy and anticoagulant agents in patients with COVID-19. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 262-264.	3.0	20

#	Article	IF	Citations
19	Left bundle branch block as an electrocardiographic pattern at presentation of patients with Tako-tsubo cardiomyopathy. Journal of Cardiovascular Medicine, 2009, 10, 100-103.	1.5	18
20	Relationship between CHA 2 DS 2-VASc score, coronary artery disease severity, residual platelet reactivity and long-term clinical outcomes in patients with acute coronary syndrome. International Journal of Cardiology, 2018, 262, 9-13.	1.7	18
21	Inflammatory and Antioxidant Pattern Unbalance in "Clopidogrel-Resistant―Patients during Acute Coronary Syndrome. Mediators of Inflammation, 2015, 2015, 1-12.	3.0	17
22	Relationship between changes in platelet reactivity and ischemicÂevents following percutaneous coronary intervention: AÂmeta-regression analysis of 30 randomized trials. Atherosclerosis, 2014, 234, 176-184.	0.8	16
23	Chronic Oral Anticoagulation and Clinical Outcome in Hospitalized COVID-19 Patients. Cardiovascular Drugs and Therapy, 2022, 36, 705-712.	2.6	15
24	Interrelation between midwall mechanics and longitudinal strain in newly diagnosed and never-treated hypertensive patients without clinically defined hypertrophy. Journal of Hypertension, 2020, 38, 295-302.	0.5	14
25	Echocardiographic Longitudinal Strain Analysis in Heart Failure: Real Usefulness for Clinical Management Beyond Diagnostic Value and Prognostic Correlations? A Comprehensive Review. Current Heart Failure Reports, 2021, 18, 290-303.	3.3	14
26	Clinical events beyond one year after an acute coronary syndrome: insights from the RECLOSE 2-ACS study. EuroIntervention, 2017, 12, 2018-2024.	3.2	13
27	Efficacy and safety of alternative oral administrations of P2Y12â€receptor inhibitors: Systematic review and metaâ€analysis. Journal of Thrombosis and Haemostasis, 2019, 17, 944-950.	3.8	12
28	Prominent basal and middle strain longitudinal involvement in newly-diagnosed and never treated hypertensive patients without clear-cut hypertrophy. International Journal of Cardiology, 2020, 304, 179-184.	1.7	12
29	Orodispersible Ticagrelor in Acute Coronary Syndromes. Journal of the American College of Cardiology, 2021, 78, 292-294.	2.8	12
30	Impaired Right and Left Ventricular Longitudinal Function in Patients with Fibrotic Interstitial Lung Diseases. Journal of Clinical Medicine, 2020, 9, 587.	2.4	11
31	Single, Dual, and Triple Antithrombotic Therapy in Cancer Patients with Coronary Artery Disease: Searching for Evidence and Personalized Approaches. Seminars in Thrombosis and Hemostasis, 2021, 47, 950-961.	2.7	10
32	Epidemiology, prognosis, and clinical manifestation of cardiovascular disease in COVID-19. Expert Review of Cardiovascular Therapy, 2020, 18, 531-539.	1.5	9
33	An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors. Biomolecules, 2021, 11, 785.	4.0	9
34	Residual platelet reactivity and outcomes with 5mg prasugrel therapy in elderly patients undergoing percutaneous coronary intervention. International Journal of Cardiology, 2014, 176, 874-877.	1.7	8
35	Dual antiplatelet therapy in patients with acute coronary syndrome during the coronavirus disease of 2019 pandemia: the right choice at the right time. Journal of Cardiovascular Medicine, 2020, 21, 535-537.	1.5	8
36	Prognostic impact of high residual platelet reactivity after chronic total occlusion percutaneous coronary intervention in patients with diabetes mellitus. International Journal of Cardiology, 2015, 201, 561-567.	1.7	7

#	Article	IF	CITATIONS
37	Platelet Reactivity in Hepatitis C Virus–Infected Patients on Dual Antiplatelet Therapy for Acute Coronary Syndrome. Journal of the American Heart Association, 2020, 9, e016441.	3.7	7
38	Prevalence, clinical and instrumental features of left bundle branch blockâ€induced cardiomyopathy: the CLIMB registry. ESC Heart Failure, 2021, 8, 5589-5593.	3.1	7
39	Dual Antiplatelet Therapy with 3rd Generation P2Y12 Inhibitors in STEMI Patients: Impact of Body Mass Index on Loading Dose–Response. Cardiovascular Drugs and Therapy, 2023, 37, 695-703.	2.6	7
40	Acute pulmonary embolism in COVID-19 patient: a case report of free-floating right heart thrombus successfully treated with fibrinolysis. European Heart Journal - Case Reports, 2021, 5, ytaa388.	0.6	6
41	Left atrial remodeling in heart failure: the role of sphericity index (the SPHERICAT-HF study). International Journal of Cardiovascular Imaging, 2022, 38, 1723-1732.	1.5	5
42	Cognitive behavioral therapy delivered via digital mobile application for the treatment of type 2 diabetes: Rationale, design, and baseline characteristics of a randomized, controlled trial. Clinical Cardiology, 2022, 45, 850-856.	1.8	5
43	Not-high before-treatment platelet reactivity in patients with STEMI: prevalence, clinical characteristics, response to therapy and outcomes. Platelets, 2022, 33, 390-397.	2.3	3
44	77â€∫Routine outpatients visits during SARS-CoV2 global pandemic. European Heart Journal Supplements, 2020, 22, N135-N137.	0.1	1
45	The long way to better PCI results in diabetic patients. International Journal of Cardiology, 2017, 245, 90-91.	1.7	0
46	Cangrelor-supported primary percutaneous coronary intervention in a patient with cardiogenic shock due to left main acute occlusion. Journal of Cardiovascular Medicine, 2020, 21, 616-617.	1.5	0
47	Impact of glucose-6-phosphate dehydrogenase deficiency on the severity of coronary atherosclerosis in patients with acute coronary syndromes. Journal of Cardiovascular Medicine, 2021, 22, 813-817.	1.5	0
48	211â€fImpact of smoking habits on baseline and on-treatment platelet reactivity in STEMI patients treated with third generation P2Y12. European Heart Journal Supplements, 2021, 23, .	0.1	0
49	205â€fDual antiplatelet therapy with third generation P2Y12 inhibitors in STEMI patients: impact of body mass index on high on-treatment platelet reactivity. European Heart Journal Supplements, 2021, 23, .	0.1	0
50	777â€fPrehospital ECG in patients with acute myocardial infarction during the COVID-19 pandemic. European Heart Journal Supplements, 2021, 23, .	0.1	0